NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis $5.13 -0.10 (-1.91%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$5.04▼$5.3250-Day Range$5.12▼$6.6152-Week Range$3.50▼$7.67Volume366,957 shsAverage Volume816,865 shsMarket Capitalization$639.92 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Wave Life Sciences alerts: Email Address Wave Life Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside156.7% Upside$13.17 Price TargetShort InterestHealthy2.69% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$279,555 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.05) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector66th out of 910 stocksPharmaceutical Preparations Industry25th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Wave Life Sciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.69% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently decreased by 6.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.58. Previous Next 2.5 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Wave Life Sciences this week, compared to 3 articles on an average week.Search Interest3 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,555.00 in company stock.Percentage Held by Insiders29.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Wave Life Sciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($1.05) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -9.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Wave Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Wave Life Sciences Stock (NASDAQ:WVE)Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More WVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Stock News HeadlinesAugust 24, 2024 | insidertrades.comWave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $279,555.48 in StockAugust 31, 2024 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Stock Passes Below Fifty Day Moving Average of $5.72September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 28, 2024 | americanbankingnews.comInsider Selling: Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $279,555.48 in StockAugust 24, 2024 | finance.yahoo.comInsider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE)August 15, 2024 | nz.finance.yahoo.comWave Life Sciences Ltd. (1U5.SG)August 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Q32 Bio (QTTB), Wave Life Sciences (WVE)August 12, 2024 | sg.finance.yahoo.comBRIEF-Wave Life Sciences Receives FDA Rare Pediatric Disease Designation For Wve-N531September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 12, 2024 | marketwatch.comWave Life Sciences Gets FDA Rare-Pediatric Designation for WVE-N531August 11, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?August 10, 2024 | seekingalpha.comWave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finanznachrichten.deWave Life Sciences USA, Inc.: Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 9, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Hold Rating on Wave Life Sciences (WVE)August 9, 2024 | markets.businessinsider.comPromising Therapeutic Efficacy and Robust Preclinical Data Underpin Buy Rating for Wave Life SciencesAugust 9, 2024 | msn.comJones Trading Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationAugust 9, 2024 | benzinga.comDeep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)August 9, 2024 | msn.comWave Life Sciences GAAP EPS of -$0.25 misses by $0.07, revenue of $19.69M beats by $0.24MSee More Headlines Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Stock Price Target$13.17 High Stock Price Target$19.00 Low Stock Price Target$5.00 Potential Upside/Downside+156.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-66.50% Pretax Margin-67.11% Return on Equity-1,395.99% Return on Assets-31.99% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$113.31 million Price / Sales5.65 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-171.00Miscellaneous Outstanding Shares124,740,000Free Float86,835,000Market Cap$639.92 million OptionableOptionable Beta-1.13 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Paul B. Bolno M.B.A. (Age 50)M.D., President, CEO & Director Comp: $1.13MMr. Kyle B. Moran CFA (Age 53)CFO & Principal Accounting Officer Comp: $726.34kDr. Chandra Vargeese Ph.D. (Age 63)Chief Technology Officer Comp: $731.8kDr. Erik IngelssonChief Scientific OfficerKate RauschHead of Investor RelationsMs. Linda Rockett J.D.Senior VP & General CounselDr. Christopher Francis Ph.D. (Age 46)Senior VP of Corporate Development & Head of Emerging Areas Comp: $493.13kMs. Daryn LewisSenior VP & Head of Human ResourcesDr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsMs. Anne-Marie Li-Kwai-CheungChief Development OfficerMore ExecutivesKey CompetitorsUroGen PharmaNASDAQ:URGNAkebia TherapeuticsNASDAQ:AKBAMarinus PharmaceuticalsNASDAQ:MRNSSpero TherapeuticsNASDAQ:SPRORAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsPaul BolnoSold 48,366 sharesTotal: $279,555.48 ($5.78/share)Point72 Asset Management L.P.Sold 1,859,259 shares on 8/19/2024Ownership: 0.094%Driehaus Capital Management LLCBought 348,300 shares on 8/16/2024Ownership: 0.728%The Manufacturers Life Insurance Company Bought 4,914 shares on 8/15/2024Ownership: 0.112%AQR Capital Management LLCBought 6,973 shares on 8/15/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? Wave Life Sciences' stock was trading at $5.05 at the beginning of the year. Since then, WVE shares have increased by 1.6% and is now trading at $5.13. View the best growth stocks for 2024 here. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) released its earnings results on Thursday, August, 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.09. The firm had revenue of $19.69 million for the quarter, compared to analysts' expectations of $24.80 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 1,395.99% and a negative net margin of 66.50%. What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are Wave Life Sciences' major shareholders? Top institutional shareholders of Wave Life Sciences include Maverick Capital Ltd. (6.15%), M28 Capital Management LP (4.94%), Primecap Management Co. CA (2.18%) and Emerald Advisers LLC (2.04%). Insiders that own company stock include Ra Capital Management, LP, Paul Bolno, Chandra Vargeese, Kyle Moran and Chris Francis. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Aduro Biotech (ADRO). This page (NASDAQ:WVE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Wave Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
